Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M25/00—Catheters; Hollow probes
  • A61M25/10—Balloon catheters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
  • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
  • A61B18/14—Probes or electrodes therefor
  • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B5/00—Measuring for diagnostic purposes; Identification of persons
  • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
  • A61B5/053—Measuring electrical impedance or conductance of a portion of the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B5/00—Measuring for diagnostic purposes; Identification of persons
  • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
  • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
  • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
  • A61B5/6852—Catheters
  • A61B5/6853—Catheters with a balloon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
  • A61L29/08—Materials for coatings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
  • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
  • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
  • A61L29/16—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M25/00—Catheters; Hollow probes
  • A61M25/10—Balloon catheters
  • A61M25/104—Balloon catheters used for angioplasty
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
  • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
  • A61B18/24—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B2018/00053—Mechanical features of the instrument of device
  • A61B2018/00107—Coatings on the energy applicator
  • A61B2018/00154—Coatings on the energy applicator containing and delivering drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B2018/00053—Mechanical features of the instrument of device
  • A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B2018/00053—Mechanical features of the instrument of device
  • A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
  • A61B2018/0022—Balloons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B2018/00636—Sensing and controlling the application of energy
  • A61B2018/00898—Alarms or notifications created in response to an abnormal condition
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
  • A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
  • A61B2018/1861—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves with an instrument inserted into a body lumen or cavity, e.g. a catheter
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
  • A61L2300/606—Coatings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M25/00—Catheters; Hollow probes
  • A61M25/10—Balloon catheters
  • A61M2025/1043—Balloon catheters with special features or adapted for special applications
  • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M25/00—Catheters; Hollow probes
  • A61M25/10—Balloon catheters
  • A61M2025/1043—Balloon catheters with special features or adapted for special applications
  • A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M25/00—Catheters; Hollow probes
  • A61M25/10—Balloon catheters
  • A61M2025/1043—Balloon catheters with special features or adapted for special applications
  • A61M2025/1088—Balloon catheters with special features or adapted for special applications having special surface characteristics depending on material properties or added substances, e.g. for reducing friction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
  • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N7/00—Ultrasound therapy
  • A61N7/02—Localised ultrasound hyperthermia
  • A61N7/022—Localised ultrasound hyperthermia intracavitary

Definitions

• the present invention is generally related to medical devices, systems, and methods.
• the invention provides methods and systems for selective drug delivery to body tissue disposed about a lumen using a catheter-based treatment system.
• Physicians use catheters to gain access to and repair interior tissues of the body, particularly within the lumens of the body such as blood vessels.
• balloon angioplasty and other catheters often are used to open arteries that have been narrowed due to atherosclerotic disease.
• Balloon angioplasty is often effective at opening an occluded blood vessel, but the trauma associated with balloon dilation can impose significant injury, so that the benefits of balloon dilation may be limited in time.
• Stenting in conjunction with balloon dilation, is often the preferred treatment for atherosclerosis.
• a collapsed metal framework is mounted on a balloon catheter which is introduced into the body.
• the stent is manipulated into the site of occlusion and expanded in place by the dilation of the underlying balloon. Stenting has gained widespread acceptance, and produces generally acceptable results in many cases.
• stents can also be used in treating many other tubular obstructions within the body, such as for treatment of reproductive, gastrointestinal, and pulmonary obstructions. Restenosis or a subsequent narrowing of the body lumen after stenting has occurred in a significant number of cases.
• drug coated stents such as Johnson and Johnson's Cypher stent, the associated drug comprising Sirolimus
• drug coated stents have demonstrated a markedly reduced restenosis rate
• others are developing and commercializing alternative drug eluting stents.
• drug eluting stents appear to offer significant promise for treatment of atherosclerosis in many patients, there remain many cases where stents either cannot be used or present significant disadvantages.
• stenting leaves an implant in the body.
• Such implants can present risks, including mechanical fatigue, corrosion, thrombus formation, and the like, particularly when removal of the implant is difficult and involves invasive surgery.
• Stenting may have additional disadvantages for treating diffuse artery disease, for treating bifurcations, for treating areas of the body susceptible to crush, and for treating arteries subject to torsion, elongation, and shortening.
• the present invention generally provides devices, systems, and methods for selective drug or fluid delivery to a body tissue being disposed about a lumen.
• the invention comprises a system for selective drug delivery to a body tissue being disposed about a lumen.
• the system includes an elongated flexible catheter body having a proximal end and a distal end with a radially expandable balloon near the distal end of the catheter body.
• An energy delivery surface disposed about the expandable balloon and a thermally changeable drug coating is coupled to the balloon, the energy delivery surface and the thermally changeable coating being oriented to be urged against the body tissue when the expandable balloon expands.
• An energy source is operatively coupled to the energy delivery surface configured to energize the energy delivery surface to heat and liquefy the thermally changeable coating to release the drug to the body tissue.
• the invention comprises a method for selective drug delivery in a lumen.
• the method includes engaging a body tissue disposed about the lumen with an energy delivery surface and a thermally changeable coating having a releasable drug disposed on a radially expandable balloon near a distal end of a catheter when the expandable balloon expands, selectively energizing the energy delivery surface to heat and liquefy portions of the thermally changeable drug coating, and releasing a drug from the coating into the body tissue.
• the energy delivery surface comprises a plurality of electrodes, the energy source operatively coupled to the plurality of electrodes so as to selectively energize electrode pairs to heat and liquefy portions of the thermally changeable coating between the electrode pairs to release the drug to the body tissue.
• the body tissue of the lumen includes a diseased portion and select electrode pairs are energized to selectively heat the thermally changeable coating proximate the diseased portion.
• the energy delivery surface comprises a plurality of electrodes disposed about the expandable balloon so as to define a plurality of remodeling zones in the tissue when the balloon is expanded within the lumen, the electrodes are radially coupled with the tissue, and energy is transmitted between the electrodes and the tissue.
• a tissue analyzer configured to characterize the body tissue.
• the energy delivery surface is energized to heat the thermally changeable coating to release the drug in responses to the characterized body tissue.
• the body tissue of the lumen includes a diseased portion and select electrode pairs are energized to selectively heat the thermally changeable coating proximate the diseased portion.
• the energy delivery surface is energized to heat the body tissue in combination with the drug delivery.
• the thermally changeable drug coating includes more than one drug
• the drug is selected from at least one of, a therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti- thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at the electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.
• the invention comprises a catheter system for drug delivery to a body tissue being disposed about a lumen.
• the system includes an elongated flexible catheter body having a proximal end and a distal end, a radially expandable balloon near the distal end of the catheter body, and an energy delivery surface disposed about the expandable balloon.
• a plurality of biomolecules having a thermally releasable drug portion and an inert portion covalently bound to the balloon and an energy source operatively coupled to the energy delivery surface so as to heat the biomolecules to release the drug portion to the body tissue.
• the invention comprises a method for fluid delivery in a lumen.
• the method includes engaging a body tissue disposed about the lumen with an energy delivery surface and a plurality of biomolecules having a thermally releasable drug portion and an inert portion covalently bound to the balloon near a distal end of a catheter when the expandable balloon expands, energizing the energy delivery surface to heat the biomolecules, and releasing the drug portion from the biomolecules into the body tissue.
• the energy delivery surface comprises a plurality of electrodes, the energy source operative Iy coupled to the plurality of electrodes so as to selectively energize electrode pairs to heat the biomolecules between the electrode pairs to release the drug portion to the body tissue.
• the body tissue of the lumen includes a diseased portion and select electrode pairs are energized to selectively heat the biomolecules proximate the to the diseased portion.
• the energy delivery surface and biomolecules are oriented to be urged against the body tissue when the expandable balloon expands.
• tissue analyzer configured to characterize the body tissue and the energy delivery surface is energized to heat the biomolecules to release the drug portion in responses to the characterized body tissue.
• the energy delivery surface is further energized to heat the body tissue in combination with the drug delivery.
• the biomolecules include more than one releasable drug.
• the drug portion is selected from at least one of, a therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at the electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.
• the invention comprises a catheter system for selective fluid delivery to a body tissue being disposed about a lumen.
• the system includes an elongated flexible catheter body having a proximal end and a distal end, a radially expandable structure near the distal end of the catheter body, a plurality of fluid delivery channels oriented to be urged against the body tissue when the expandable structure expands, the fluid delivery channels being initially blocked with a thermally changeable material, and an energy source connector operatively coupled to the fluid delivery channels so as to heat and liquefy the thermally changeable material to selectively open one or more of the fluid delivery channels for fluid release.
• the invention comprises a catheter system for selective fluid delivery to a body tissue being disposed about a lumen.
• the system includes an elongated flexible catheter body having a proximal end and a distal end, a radially expandable structure near the distal end of the catheter body, a plurality of fluid delivery channels oriented to be urged against the body tissue of the lumen when the expandable structure expands, the fluid delivery channels being initially closed, and a plurality of micro-electromechanical systems (MEMS) coupled to the fluid delivery channels to selectively open one or more fluid delivery channels and release a fluid in the lumen.
• MEMS micro-electromechanical systems
• the invention comprises a method for selective fluid delivery in a lumen.
• the method includes engaging a body tissue disposed about the lumen with a plurality of fluid delivery channels on a radially expandable structure near a distal end of a catheter when the expandable structure expands, selectively opening one or more fluid delivery channels, and releasing a fluid from the select fluid delivery channels into the lumen.
• the plurality of fluid delivery channels protrude from the expandable structure to penetrate the body tissue of the lumen.
• tissue analyzer configured to characterize the body tissue to identify body tissue to be treated and selectively opening or closing one or more fluid delivery channels in responses to the characterized body tissue to treat the identified body tissue.
• the fluid delivery channels can be selectively energized to selectively open one or more fluid delivery channels in responses to the characterized body tissue.
• the radially expandable structure comprises a balloon and the fluid delivery channels are mounted on a circumference of the balloon.
• the radially expandable structure comprises an expandable basket and the fluid delivery channels are mounted on a circumference of the basket.
• the body tissue of the lumen includes a diseased portion and select electrodes are energized to selectively open one or more fluid delivery channels proximate the diseased portion.
• select electrodes are energized to heat the body tissue in conjunction with the release of the fluid in the lumen.
• selectively opening one or more fluid delivery channels comprises selectively energizing electrodes coupled to the select fluid delivery channels to heat the select fluid delivery channels to liquefy a thermal material initially closing the fluid delivery channel.
• the fluid is selected from at least one of, ceramide, suramin, rapamycin, paclitaxel, sirolimus, zotarolimus, everolimus, a therapeutic fluid, an anesthetic drug, a therapeutic drug, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at an electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.
• the invention comprises a method for selective fluid delivery in a lumen.
• the method includes engaging a body tissue disposed about the lumen with a plurality of fluid delivery channels on a radially expandable structure near a distal end of a catheter when the expandable structure expands, the balloon material is a membrane of a fixed pore size, and adding energy or heat to the fluid adjacent to the balloon surface allows the specific molecules to be passed through the membrane at the specific region for the specific time by virtue of the energy/heat source being switched on or off.
• FIG. 1 schematically illustrates one embodiment of a catheter system having a coating for selective drug delivery to a body tissue being disposed about a lumen.
• FIG. 2 schematically illustrates one embodiment of an inflatable balloon for use in the catheter system of FIG. 1.
• FIG. 3A schematically illustrates a cross-sectional view and 3B is an enlarged view of the balloon of FIG. 2.
• FIGs. 4A and 4B schematically illustrates coatings covering the electrodes.
• FIG. 5 schematically illustrates the used of aptamers in treating tissue.
• FIG. 6 schematically illustrates placement of electrode pairs for use in bipolar energy treatment before, during, or after drug delivery.
• FIG. 7 schematically illustrates another embodiment of a catheter system having fluid delivery channels for selective fluid delivery to a body tissue being disposed about a lumen.
• FIG. 8A schematically illustrates a cross-section and FIG. 8B is an enlarged section of the balloon in FIG. 7 showing fluid delivery channels through the balloon coupled to electrodes mounted on a surface of the balloon.
• FIGs. 9A and 9B schematically illustrate cross-sectional views showing tissue treatment using biomolecules having a thermally releasable active portion and an inert portion coupled by covalent bond to a balloon surface.
• FIG. 10 schematically illustrates another embodiment of a balloon having a membrane for selective drug delivery to a body tissue being disposed about a lumen.
• the present invention discloses systems and methods for selective delivery of a fluid to body tissue in a lumen, in particular, selective drug delivery in a lumen. Selective delivery may also control when and where the drug is delivered, and the amount of drug delivered.
• ceramide a therapeutic fluid
• suramin rapamycin
• paclitaxel sirolimus
• zotarolimus everolimus
• a drug ananesthetic or therapeutic
• suitable fluids may be also be delivered to body tissue, for example, a therapeutic fluid, a small molecule, a gene therapeutic compound, an anti-thrombolytic agent, a lubricant (to allow higher temperatures without sticking), an electrically conductive compound to lower the impedance at the electrode, an electrically insulating compound to prevent treatment to tissue that does not need treatment, an electrically conductive compound that is intended to migrate through the endothelial layers of tissue to carry energy to the interstitial layers, or a combination of the above.
• a drug is incorporated into a coating on a balloon catheter that is thermally released once inside the lumen to selectively treat the tissue.
• a fluid or drug may be delivered through fluid delivery channels in a catheter system to selectively treat the tissue.
• multiple fluids or drugs may be delivered as part of a coating, through the fluid delivery channels, by thermal osmosis through a membrane, or any combination thereof.
• the drug may be delivered at one tissue site, while other embodiments portions of the drug to different sites.
• Some embodiments of the present invention use heating to release the drug coating.
• Other embodiments combine fluid or drug delivery with heating of the tissue before, during or after delivery to the tissue.
• Devices for heating artery tissue using RF, ultrasound, microwave and laser energies have been disclosed in co-pending U.S. Patent Application Nos. 11/975,474, 11/975,383, 11/122,263 and U.S. Provisional Application No. 61/099,155, the full disclosures of which are incorporated herein by reference.
• Some embodiments of the present invention provide systems and methods for drug delivery in a lumen in combination with heating during an angioplasty procedure. While drugs are disclosed, proteins, cells and/or molecules may also be delivered (discussed below).
• the angioplasty procedure itself is the procedure that will open the lumen. The heating will cause softening and shrinking of a lesion, enabling the plaque to reshape easily around the balloon while avoiding stretching of the vessel thus avoiding injury to the vessel.
• the drug will be released during the angioplasty procedure and the heating process.
• Drug delivery treatment during an angioplasty procedure will be a combination of:
• the pressure may be standard angioplasty dilation pressures of 10-16 atmospheres or may be more gentle dilation pressures of 6 atmospheres or less, and possibly as low as 1 to 2 atmospheres.
• Heating due to the RF energy in order to soften and shrink the lesion. Heating may also have other benefits related to the drug or drug delivery (discussed below).
• the Drug/Molecule/Protein/Cell element can be built of one component, or in combination of others such as:
• Drugs any molecule which will enable prevention or reduction of smooth muscle cell (SMC) proliferation and/or migration from the media to the intima, for example: ceramide, suramin, rapamycin and paclitaxel.
• SMC smooth muscle cell
• the heating of the tissue may have a key role in helping deliver the drug into the lesion or tissue, and deeper into the media.
• Proteins proteins such as anti-inflammatory proteins, antibodies and other kinds of proteins which will enable the reduction and healing of the inflammation inside the lesion, or enable prevention or reduction of SMC proliferation and migration.
• proteins proteins that will induce cell apoptosis or oncosis.
• the heating may have a key role in activating these proteins during the treatment, and if heated quickly during the procedure, enabling the maximum time exposure of the tissue to the proteins.
• the half-life of a protein is the time it takes before any half of the protein pool for that particular protein is left, for human proteins, it ranges from minutes to 80 hours.
• ATP Adenosine-5'-triphosphate
• the balloon is covered with the protein and the electrodes are covered with ATP (or the opposite) and the protein will be released with the balloon inflation, and the ATP will be released when the energy will be emitted from the electrodes (or the opposite).
• HSP heat shock proteins
• SMC smooth muscle cells
• Fig. 1 shows one embodiment of a catheter system 10 having a releasable coating for selective drug delivery to a body tissue being disposed about a lumen.
• the catheter system 10 includes a balloon catheter 12 having a catheter body 14 with a proximal end 16 and a distal end 18.
• Catheter body 14 is flexible and defines a catheter axis 15, and may include one or more lumens, such as a guidewire lumen 22 and an inflation lumen 24.
• Catheter 12 includes an inflatable balloon 20 adjacent distal end 18 and a housing 29 adjacent proximal end 16.
• Housing 29 includes a first connector 26 in communication with guidewire lumen 22 and a second connector 28 in fluid communication with inflation lumen 24.
• Inflation lumen 24 extends between balloon 20 and second connector 28.
• Both first and second connectors 26, 28 may optionally comprise a standard connector, such as a Luer-LocTM connector.
• a distal tip may include an integral tip valve to allow passage of guidewires, and the like.
• Housing 29 also accommodates an electrical connector 38.
• Connector 38 includes a plurality of electrical connections, each electrically coupled to electrodes 34 via conductors 36. This allows electrodes 34 to be easily energized, the electrodes often being energized by a controller 40 and power source 42, such as RF energy.
• electrical connector 38 is coupled to an RF generator via a controller 40, with controller 40 allowing energy to be selectively directed to electrodes 34.
• RF energy is disclosed
• suitable energy sources such as microwave energy, ultrasound energy, or laser energy, each having energy delivery portions configured to deliver the desired energy. See copending U.S. Provisional Application No. 61/099,155, the full disclosures of which are incorporated herein by reference.
• controller 40 may include a processor or be coupled to a processor to control or record treatment.
• the processor will typically comprise computer hardware and/or software, often including one or more programmable processor unit running machine readable program instructions or code for implementing some or all of one or more of the methods described herein.
• the code will often be embodied in a tangible media such as a memory (optionally a read only memory, a random access memory, a non-volatile memory, or the like) and/or a recording media (such as a floppy disk, a hard drive, a CD, a DVD, a nonvolatile solid-state memory card, or the like).
• the code and/or associated data and signals may also be transmitted to or from the processor via a network connection (such as a wireless network, an Ethernet, an internet, an intranet, or the like), and some or all of the code may also be transmitted between components of catheter system 10 and within processor via one or more bus, and appropriate standard or proprietary communications cards, connectors, cables, and the like will often be included in the processor.
• a network connection such as a wireless network, an Ethernet, an internet, an intranet, or the like
• Processor will often be configured to perform the calculations and signal transmission steps described herein at least in part by programming the processor with the software code, which may be written as a single program, a series of separate subroutines or related programs, or the like.
• the processor may comprise standard or proprietary digital and/or analog signal processing hardware, software, and/or firmware, and will typically have sufficient processing power to perform the calculations described herein during treatment of the patient, the processor optionally comprising a personal computer, a notebook computer, a tablet computer, a proprietary processing unit, or a combination thereof.
• Standard or proprietary input devices such as a mouse, keyboard, touchscreen, joystick, etc.
• output devices such as a printer, speakers, display, etc.
• processors having a plurality of processing units may be employed in a wide range of centralized or distributed data processing architectures.
• Balloon 20 is illustrated in more detail in Fig. 2.
• Balloon 20 generally includes a proximal portion 30 coupled to inflation lumen 24 and a distal portion 32 coupled to guidewire lumen 22.
• Balloon 20 expands radially when inflated with a fluid or a gas.
• the fluid or gas may be non-conductive and/or cooled.
• balloon 20 may be a low pressure balloon pressurized to contact the artery tissue.
• balloon 20 is an angioplasty balloon capable of higher pressure to both heat the artery tissue and expand the artery lumen.
• Balloon 20 may comprise a compliant or non- compliant balloon having helical folds to facilitate reconfiguring the balloon from a radially expanded, inflated configuration to a low profile configuration, particularly for removal after use.
• Electrodes 34 are mounted on a surface of balloon 20, with associated conductors 36 extending proximally from the electrodes. Electrodes 34 may be arranged in many different patterns or arrays on balloon 20. The system may be used for monopolar or bipolar application of energy. For delivery of bipolar energy, adjacent electrodes are axially offset to allow bipolar energy to be directed between adjacent circumferential (axially offset) electrodes. In other embodiments, electrodes may be arranged in bands around the balloon to allow bipolar energy to be directed between adjacent distal and proximal electrodes.
• a coating 35 is coupled to the balloon 20 and positioned between electrodes 34, such as shown in FIGs. 3A and 3B.
• Coating 35 includes a fluid or drug to be delivered to the targeted tissue. It is envisioned that the coating will be thermally activated and configured to be released from the balloon surface at a temperature above body temperature (greater than 37C). The idea is to have the energy delivery or heat, change the phase of a coating compound from a solid to a liquid, and releases the drug. This temperature increase involves activating electrodes 34 using RF energy. As the energy is increased, the coating 35 between the electrodes 34 is heated and released thermally to the local tissue 48. Coating 35 is durable or flexible such that it can be folded with the balloon 20 without separation or delamination.
• a second coating 35 A may be used to cover electrodes 34, such as shown in FIG. 4 A.
• Second coating 35 A may be an insulating coating on the electrodes 34.
• the second coating 35A would be used when treating inside a metallic object in the lumen, such as a stent, because if the electrodes 34 come in contact with metal, they may short and the treatment will end. If the electrodes 34 are coated with a material with electrical properties such that the electrodes can not be shorted with metallic objects, the treatment can continue even when in contact with metal objects. This would allow catheter system 10 to treat inside objects like stents.
• Second coating 35 A may also act to insulate electrodes 34 from tissue 48, shown in FIG. 4B, which stops/prohibits energy flow through tissue 48 and sends the energy through coating 35, heating only the coating 35 between the electrodes 34, releasing the drug to the tissue 48.
• the second coating 35A may also include a different drug than coating 35.
• the coating may include drugs currently used in drug eluding stents, such as sirolimus (used in the CypherTM stent), paclitaxel (used in the TaxusTM stent), zotarolimus (used in the EndeavourTM stent) and everolimus (used in the Xience VTM stent).
• drugs currently used in drug eluding stents such as sirolimus (used in the CypherTM stent), paclitaxel (used in the TaxusTM stent), zotarolimus (used in the EndeavourTM stent) and everolimus (used in the Xience VTM stent).
• Some embodiments of the present invention may include aptamers 52 coated to the balloon 20 using a substrate that breaks down readily when heated, such as when the RF energy source is activated.
• Aptamers can be engineered to bind very specifically to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues and organisms.
• the aptamers 52 could be synthesized to bind 54 with desired tissue 48 to be treated, such as plaque, within the lumen or artery.
• aptamers 52 While the catheter system 10 is not powered and the balloon 20 deflated, the coating 35 with aptamers 52 would remain on the balloon 20. Once the balloon 20 is inflated and the energy unit turned on, the coating is released and the aptamers 52 bind to the desired tissue, such as shown in FIG. 5. In some embodiments, aptamers 52 would be conjugated to a microscopic bead 56 that is highly receptive to the energy 58, such as RF energy, emitted by the catheter system 10. The beads 56 convert the RF energy to thermal energy directly and only to the tissue that the aptamers 52 is in contact with.
• the energy 58 such as RF energy
• Aptamers are nucleic acids that bind to the surface of molecules in much the same way as antibodies.
• One importance difference between aptamers and antibodies is that aptamers can be produced by chemical synthesis whereas antibodies are produced biologically, first animals, then in culture or an expression system.
• Another important difference is that aptamers are very stable and not sensitive to their surrounding environment, including temperature.
• coating 35 may include a chemical solvent that has plaque softening properties.
• Ether, chloroform, benzene, and acetone are known to be lipid solvents.
• amino acids, proteins, carbohydrates, and nucleic acids are largely insoluble in these solvents. If the solvent is used in conjunction with tissue heating, the tissue treatment may require less energy over a shorter time period, lessening the chance of damage to healthy tissue. If the tissue includes calcium deposits, the same process used to deliver lipid solvents to plaque could be used to deliver calcium solvents to calcification sites. Calcium is highly soluble in a variety of organic solvents. In both cases, the solvent would be coupled to the surface of the balloon with a coating that would break down either with the application of heat or RF energy, or as the balloon is inflated.
• the coating may incorporate more than one drug, agent, or fluid listed herein within the coating, each having different phase change temperatures.
• an anesthetic could be administered at a lower melting temperature prior to a specific treatment of higher temperature where there may be a nerve in the general location.
• two coatings of differing material may be used, such as by layering.
• a first layer may include a first drug that attaches to the target tissue and act as a receptor to a second drug in a second layer.
• the coating is non-conductive to reduce or eliminate electrical shorts between electrodes.
• tissue signature could be used to identify treatment regions with the use of impedance measurements.
• Impedance measurements utilizing the radially spaced electrodes 34 within a lumen can be used to analyze tissue. Impedance measurements between pairs of adjacent electrodes (and/or between pairs of separated electrodes), may differ when the current path passes through diseased tissue, and when it passes through healthy tissues of the luminal wall. Hence, impedance measurements between the electrodes on either side of diseased tissue may indicate a lesion, while measurements between other pairs of adjacent electrodes indicate healthy tissue.
• Other characterization such as intravascular ultrasound, optical coherence tomography, or the like may be used to identify regions to be treated.
• Some embodiments described herein may be used to treat atherosclerotic disease by selective drug delivery in combination with "gentle heating” utilizing the “QlO Rule” to further enhance the fluid or drug treatment.
• QlO Rule it is well known that rates of biochemical reactions usually double when temperature is increased by 10°C.
• electrodes 34 are positioned circumferentially around the balloon 20.
• RF energy 43 is directed to electrodes adjacent pairs of electrodes 34A and 34C, or 34A and 34D, or any combination of 34A-34D, treating both the healthy tissue 45 and atherosclerotic material 48 within lumen 50.
• This arrangement creates an energy path 43 through the tissue that delivers energy or heat ("tissue remodeling energy") in particular treatment zones or segments to the artery tissue between the electrode pairs ("remodeling zones”) having a volume between the electrode pairs at a specific depth.
• tissue remodeling energy energy
• Using different combinations of electrode pairs may reduce or eliminate gaps between the remodeling zones by using overlapping pairs.
• Using electrode pairs with bipolar energy may avoid some potential issues of the monopolar approach.
• Diseased artery tissue 48 has a higher electrical resistivity than healthy artery tissue.
• tissue remodeling energy will go through the healthy tissue, diseased tissue, or a combination of both healthy and diseased tissues between the electrode pairs in the remodeling zones. Any number of electrode pairs may be used in different patterns or arrays to create a number of remodeling zones.
• the controller may apply either constant power, constant current, or constant voltage, whichever has the most advantage.
• the controller 40 may energize the electrodes with about 0.25 to 5 Watts average power for 1 to 180 seconds, or with about 4 to 45 Joules. Higher energy treatments are done at lower powers and longer durations, such as 0.5 Watts for 90 seconds or 0.25 Watts for 180 seconds. Most treatments in the 2 to 4 Watt range are performed in 1 to 4 seconds. Using a wider electrode spacing, it would be appropriate to scale up the power and duration of the treatment, in which case the average power could be higher than 5 Watts, and the total energy could exceed 45 Joules. Likewise, using a shorter or smaller electrode pair would require scaling the average power down, and the total energy could be less than 4 Joules.
• the power and duration are calibrated to be less than enough to cause severe damage, and particularly less than enough to ablate diseased tissue 48 within a blood vessel.
• the delivery of the drug and gentle heat may be accompanied by balloon angioplasty using gentle dilation to remodel the artery with dilation pressures which are at or significantly lower than standard, unheated angioplasty dilation pressures.
• balloon inflation pressures of 10-16 atmospheres may, for example, be appropriate for standard angioplasty dilation of a particular lesion
• modified dilation treatments combined with appropriate electrical potentials (through flexible circuit electrodes on the balloon, electrodes deposited directly on the balloon structure, or the like) described herein may employ from 10-16 atmospheres or may be effected with pressures of 6 atmospheres or less, and possibly as low as 1 to 2 atmospheres.
• Such moderate dilations pressures may (or may not) be combined with one or more aspects of the tissue characterization, tuned energy, eccentric treatments, and other treatment aspects described herein for treatment of diseases of the peripheral vasculature.
• drug clotting balloons have shown an even greater reduction in the frequency of restenosis than drug eluting stents and are removed after treatment, however, high pressure inflation is required to optimally deliver the anti-proliferation/anti-inflammatory biomolecules.
• the molecules may function to prevent restenosis by preventing inflammatory cell influx (chemo taxis), cell proliferation.
• the molecules may also function to stabilize the IEL matrix by providing structural support, thus "setting" the lumen diameter.
• Figs. 9A and 9B show another embodiment of a catheter system 200 for drug delivery to a body tissue 248.
• the system 200 is similar to system 10 above, except the use of biomolecules 235 coupled to the balloon 20 instead of a coating.
• the biomolecules 235 include a thermally releasable active portion 235a and an inert portion 235b coupled by covalent bond to a balloon 20 surface.
• the active portion or molecule 235b is capable of treating the desired tissue 248, which may be enhanced with temperature or pressure.
• the inert portion 235a of the biomolecule stays on the balloon.
• the embodiment described herein utilizes a radiofrequency endovascular balloon catheter that, upon low pressure inflation and energy delivery from the balloon to the atherosclerotic lesion, hyper-thermally releases the active portion of the biomolecule that is covalently bound to the balloon, thus, delivering the active portion of the molecule to the targeted tissue.
• the energy may also include ultrasound emitting energy.
• the active molecule 235b functions to prevent production of hyperplastic tissue by any means, including, but not limited to, cytostasis (prevention of mitosis), receptor maturation (i.e., those receptors at/on cells on the targeted tissue that are adhesive to/for a chemotactic to/for infiltrating cells that promote hyperplasic tissue formation.
• the molecule's bioactive portion 235b is released from the intact biomolecule 235 by delivery of energy (such as from electrodes 34) that induces a local hyperthermia environment.
• energy such as from electrodes 34
• the molecule is stable under the hyperthermia conditions.
• the molecule can prevent one or all of the following functions:
• the influx of the molecule 235b into the diseased tissue 48 is facilitated and/or hastened by the energy mediated hypothermia, i.e., cleavage from the intact biomolecule, migration into the diseased tissue, and residence in the diseased tissue by virtue of increased porosity are all accelerated by the hyperthermia.
• This invention uniquely delivers a bioactive molecule into diseased tissue with:
• Clinical application and uses are designed to reduce plaque, inhibit restenosis in stented or not-stented site, and may be used as an adjunctive treatment to aggressive non-implantable endovascular procedures and stent implants.
• Fig. 7 shows another embodiment of a catheter system 100 having fluid delivery channels for selective fluid delivery to a body tissue being disposed about a lumen.
• the catheter system 100 includes a balloon catheter 112 having a catheter body 114 with a proximal end 116 and a distal end 118.
• Catheter body 114 is flexible and defines a catheter axis 115, and may include one or more lumens, such as a guidewire lumen 122 and an inflation lumen 124.
• Catheter 112 includes an inflatable balloon 120 adjacent distal end 118 and a housing 129 adjacent proximal end 116.
• Housing 129 includes a first connector 126 in communication with guidewire lumen 122 and a second connector 128 in fluid communication with inflation lumen 124.
• Inflation lumen 124 extends between balloon 120 and second connector 128.
• Both first and second connectors 126, 128 may optionally comprise a standard connector, such as a Luer-LocTM connector.
• a distal tip may include an integral tip valve to allow passage of guidewires, and the like.
• Housing 129 also accommodates an electrical connector 138.
• Connector 138 includes a plurality of electrical connections, each electrically coupled to electrodes 134 via conductors 136. This allows electrodes 134 to be easily energized, the electrodes often being energized by a controller 140 and power source 142, such as RF energy, microwave energy, ultrasound energy, or other suitable energy sources.
• electrical connector 138 is coupled to an RF generator via a controller 140, with controller 140 allowing energy to be selectively directed to electrodes 134 or electrode pairs.
• Controller 140 may include a processor or be coupled to a processor to control or record treatment.
• FIG. 8A shows a cross-section of the balloon 120 and FIG. 8B is an enlarged section showing fluid delivery channels 160 through the balloon 120 coupled to electrodes 134 mounted on a surface of balloon 120.
• Electrodes 134 include associated conductors extending proximally from the electrodes. Electrodes 134 and fluid delivery channels 160 may be arranged in many different patterns or arrays on balloon 120. Fluid delivery channels 160 may be coupled to a fluid reservoir or lumen 162 holding the fluid 152.
• the inflation medium may contain the fluid to be delivered.
• the channels 160 thru balloon 120 may be filled with wax-like material 164 that can be expelled thermally in order to open the channel (or any other material that can be expelled).
• electrodes 134 may open and close a flap to release the fluid.
• the delivery channels 160 may protrude from the balloon surface such that they are capable of penetrating the body tissue of the lumen.
• the electrodes may penetrate the body tissue.
• the catheter system 100 may also include a tissue analyzer configured to characterize the body tissue.
• electrodes 134 may be sensing electrodes, as discussed above, that could help characterize the tissue to identify regions the be treated or not using electrical impedance tomography. Other characterization, such as intravascular ultrasound, optical coherence tomography, or the like may be used to identify regions to be treated. Electrodes 134 may be energized in response to the characterized body tissue
• Some embodiments described herein may be used to treat atherosclerotic disease by selective fluid delivery in combination with "gentle heating" to further enhance the fluid delivery or treatment, as discussed above.
• Electrodes 134 may be selectively energized to open or close fluid delivery channels 160 to treat tissue.
• One method includes opening the fluid delivery channels 160 by selectively heating the electrodes (by Joule heating or other means, including inducing a heightened temperature in the adjacent region, whereby hear transfer could heat the electrode(s)), such that a material 164, that would otherwise block the channel, is phase changed from solid to liquid.
• Another possible method may include the use of MEMS (micro-elector-mechanical-systems) to open and/or close channels 160 selectively.
• the fluid delivery channels may be vias through the electrodes (perfused electrodes).
• the vias or small holes may be used to deliver a fluid to the artery tissue proximate the electrode.
• the holes may be less than 1 ⁇ m in diameter and may be made with a laser or ion beam.
• the holes may be made in the electrodes and balloon.
• electrode pads on a flexible circuit are designed with vias that are plated.
• the flexible circuit is mounted on a balloon and a laser or ion beam is used to create the holes in the flexible substrate and balloon. There may be several holes in the flexible/balloon for every electrode pad.
• the balloon may then be perfused with standard perfusion balloon equipment or specialized equipment. This perfusion approach may also provide additional advantages beyond fluid delivery, such as eliminating sticking, carry away heat or regulate the impedance of the load.
• a porous balloon may be used having fluid delivery channels on a micro-level, allowing select molecules through with the addition of heat.
• the porous balloon may have an inner layer, a porous outer layer or membrane, drug or fluid molecules positioned between the layers (i.e., a reservoir) and electrodes coupled to the outer layer. At low pressures, the molecules stay within the reservoir.
• the molecules may go through the porous layer, which may be done in different ways. For example, as the heat is applied, the drug molecules may become exited, providing enough force to go through the porous outer layer. In another example, as heat is applied to the balloon, the pores expand, allowing the drug molecules to go through the porous outer layer.
• the molecules may also pass through the porous outer layer or membrane by osmotic pressure along with the heat.
• the treatments may include a drug, and/or thermal, and/or small or large molecules injection, and/or RF, and/or balloon dilatation, and/or hyperthermia.
• a porous balloon may be used having fluid delivery channels on a micro-level in a membrane, allowing molecules through with the addition of pressure and heat.
• the concept delivers a fluid or drug to a specific site by passing it through the membrane, much like reverse osmosis.
• reverse osmosis a pressure is used to drive a liquid, such as water, through a membrane with passages so small that only the appropriate molecules can pass through.
• the membrane barrier retains a drug, like paclitaxel. At low pressures, the drug molecules are not able to pass through the membrane.
• pressure is applied to the drug molecules using a balloon the release of the drug is the accelerated by applying energy locally by an electrode pair or monopolar electrode.
• FIG. 10 shows one embodiment of a catheter system, similar to catheter system 10, having a balloon 300 with a non-porous inner balloon 305 (to provide pressure), a porous outer layer, membrane or sleeve 310, a drug or fluid 315 positioned between inner balloon 305 and membrane 310 (i.e., a reservoir), and electrodes 320 coupled to the membrane 310. Electrodes 320 may be similar to the electrodes describe above.
• the balloon is placed at the desired tissue site and the balloon is inflated to a suitable pressure, such as 4-6 ATM.
• a suitable pressure such as 4-6 ATM.
• the devices, systems, and methods disclosed herein may be used to selectively deliver fluid in any artery, for example, the femoral, popliteal, coronary and/or carotid arteries. While the disclosure focuses on the use of the technology in the vasculature, the technology would also be useful for any luminal obstruction.
• anatomical structures in which the present invention may be used are the esophagus, the oral cavity, the nasopharyngeal cavity, the auditory tube and tympanic cavity, the sinus of the brain, the arterial system, the venous system, the heart, the larynx, the trachea, the bronchus, the stomach, the duodenum, the ileum, the colon, the rectum, the bladder, the ureter, the ejaculatory duct, the vas deferens, the urethra, the uterine cavity, the vaginal canal, and the cervical canal.
• the devices, systems, and method disclosed herein may employ one or more of a wide variety of mechanisms to facilitate, promote, and/or enhance transport of at least one drug from a fluid, gel, or solid of a catheter (or other delivery structure) toward, to and/or into a desired treatment site or tissue.
• exemplary thermally-mediated drug transport mechanisms which may be employed are described above. Additional mechanisms may also be used including electrically mediated drug transport mechanisms, optionally including mechanisms such as electroporation, ionotophoresis, and the like. Electroporation may allow targeting drug molecules intracellularly via creating passages in the cell membrane.
• Electroporation can significantly increase the electrical conductivity and permeability of the cell plasma membrane by application of an external electrical field, optionally by application of an electroporation voltage (which may involve a series of electroporation potentials) using one or more electrodes of the balloon catheters described herein.
• Iontophoresis may be employed by applying a relatively small electric potential so as to deliver a medicine or other chemical through the luminal surface, with the electrical potential again optionally being applied using one or more electrodes of the balloon catheters described hereinabove.
• anti-inflammatory molecules could be delivered via iontophoretic membranes to atherosclerotic lesions.
• Small molecule inhibitors of inflammation, thrombogenesis, and thrombosis can be delivered to atherolosclerotic lesions via iontophoretic methods using devices and systems described herein to slow or prevent progression of atherosclerosis and thrombus formation.
• suitable inflammatory and/or thrombogenic tissue targets in the artery may include platelet cell adhesion factor (PECAM), Tissue Factor (TF), matrix metalloproteinases (MMP), and/or the like.
• PECAM platelet cell adhesion factor
• TF Tissue Factor
• MMP matrix metalloproteinases
• Examples of a small molecule anti-inflammatory / anti-thrombosis therapeutics that would be amenable to delivery via iontophoresis may include heparin, heparin sulfate, and/or the like.
• suitable potentials may be applied in either a bipolar arrangement (between electrodes of the balloon catheter) or in a monopolar mode.
• Suitable potentials may be applied by commercially available iontophoresis or electroporation systems, or specialized potential generators may be employed.
• These drug transport mechanisms can optionally be combined, for example, with a thermal mechanism used (for example, by energizing electrodes so as to heat a coating, and optionally to facilitate release of a drug and thermally enhance movement of the drug into a target tissue), followed with an electrically mediated drug transport mechanism (optionally by energizing the same electrodes or different electrodes of the balloon with a suitable potential).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Surgery (AREA)
• Physics & Mathematics (AREA)
• Medical Informatics (AREA)
• Epidemiology (AREA)
• Anesthesiology (AREA)
• Pulmonology (AREA)
• Child & Adolescent Psychology (AREA)
• Hematology (AREA)
• Pathology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Radiology & Medical Imaging (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Cardiology (AREA)
• Plasma & Fusion (AREA)
• Otolaryngology (AREA)
• Vascular Medicine (AREA)
• Media Introduction/Drainage Providing Device (AREA)
• Materials For Medical Uses (AREA)
• Surgical Instruments (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42170372

Family Applications (1)

Country Status (7)

Cited By (29)

Families Citing this family (172)

Citations (8)

Family Cites Families (1241)